Animal models of X-linked juvenile retinoschisis (XLRS) are valuable tools for understanding basic biochemical function of retinoschisin (RS1) protein and to investigate outcomes of preclinical efficacy and toxicity studies. In order to work with an eye larger than mouse, we generated and characterized an Rs1h−/− knockout rat model created by removing exon 3. This rat model expresses no normal RS1 protein. The model shares features of an early onset and more severe phenotype of human XLRS. The morphologic pathology includes schisis cavities at postnatal day 15 (p15), photoreceptors that are misplaced into the subretinal space and OPL, and a reduction of photoreceptor cell numbers by p21. By 6 mo age only 1–3 rows of photoreceptors nuclei remain, and the inner outer segment layers and the OPL shows major changes. Electroretinogram recordings show functional loss with considerable reduction of both the a-wave and b-wave by p28, indicating early age loss and dysfunction of photoreceptors. The ratio of b/a-wave amplitudes indicates impaired synaptic transmission to bipolar cells in addition. Supplementing the Rs1h−/− exon3-del rat model with normal human RS1 protein using AAV8-RS1 delivery improved the retinal structure. This Rs1h−/− rat model provides a further tool to explore underlying mechanisms of XLRS pathology and to evaluate therapeutic intervention for the XLRS condition.

INTRODUCTION
Animal models of human diseases have been widely used to study features of human monogenic diseases and to explore treatment strategies. Several Rs1h−/− knockout (KO) mouse models have been generated which mimic the human pathology in X-linked juvenile retinoschisis (XLRS) patient [1–4]. All of these genetically modified mice fail to express normal retinoschisin protein, and they display structural and functional retinal phenotypes in the spectrum of XLRS patients. Histologically, retina laminar structures are disorganized with photoreceptor cells mis-localized in early to mid-stage, and the inner nuclear layer has schisis structural abnormalities. Synaptic transmission in the outer plexiform layer, as is also involved in the human XLRS disease [5, 6], and photoreceptor cells are degenerated in mid-late stages. Functionally, these mice show the characteristic reduction of dark-adapted ERG b-wave amplitudes and a reduction of the b/a-wave amplitude ratio in many XLRS patients [1]. There are currently no effective treatments for XLRS disease, and efforts are underway to ameliorate the condition using clinical AAV-mediated gene therapy (ClinicalTrials.gov.NCT 02317887 and NCT 02416622) [1, 5, 7–12].

The small eye of Rs1h-mutant mice presents a challenge to explore treatments. Injecting therapeutic agents into the small eye risks ocular damage and a rapid increase of intraocular pressure (IOP) [13] which may confound interpretation of results in pre-clinical studies [7]. In previous pre-clinical safety and toxicity study for a XLRS gene therapy trial [14], we used rabbit for some of the studies. It would be useful to have a larger animal disease model that represents XLRS human disease. Here we report results of creating and characterizing an Rs1h−/− exon3-del rat model using CRISPR/Cas 9 techniques [15–17].

MATERIALS AND METHODS
Experiments were conducted in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and with protocols approved by the National Eye Institute Animal Care and Use Committee. Normal Long Evans rats were purchased from Charles River Laboratory (Wilmington, MA) and housed under fluorescent lights in a 12-h light–dark cycle.

Generation of Rs1h−/− exon3-del rat model
The Rs1h−/− rat was generated using CRISPR/Cas9-mediated gene editing system [15–19]. Exon 3 (106 base pair) of rat Rs1h (GenBank accession number: NM_001104643.1; Ensembl: ENSRNOG00000030434) was targeted with two guide RNAs (gRNA) located in intron 2 and intron 3 to introduce two DNA breaks with Cas9 endonuclease. gRNAs and Cas9 nuclease mRNA were transcribed in vitro and were injected into the pronuclei of fertilized eggs of Long Evans rat and implanted into surrogate mothers to obtain founders. Two founders were identified by PCR genotyping and confirmed by DNA sequencing analysis. They were then bred with wildtype Long Evans to produce generation 1 (F1), and correct transmission of the mutation was confirmed by PCR genotyping and by DNA sequencing analysis. Hemizygous male (Rs1h−/−) F1 and heterozygous female (Rs1h+/−)
F1 was bred with wildtype Long Evans to establish rat colonies. The Rs1h−/− rat model was generated with assistance from Cyagen Biosciences Inc. (Santa Clara, CA, USA). Ten potential off-target sites were predicted on chromosomes 2, 3 (two sites), 4, 7, 9, 10, 14, 16, and X. These were amplified with PCR method, the absence of any of these potential mutations was verified using DNA sequencing analysis of PCR products in all F1 rats.

**Absence of normal Rs1h protein in Rs1h−/− rat model**

*Western blot analysis.* Rats were euthanized by carbon dioxide followed by bilateral pneumothorax, and retinas were dissected. Retinal extract was obtained by lysing in RIPA buffer (25 mM Tris-HCl [pH 7.6], 150 mM NaCl, 1% NP40, 1% sodium deoxycholate, 0.1% SDS) containing protease inhibitor cocktail (Thermo Scientific, Rockford, IL, USA). Protein concentrations were determined by the Pierce Bicinchoninic acid (BCA) Protein Assay Kit (Thermo Scientific, Rockford, IL, USA) with bovine serum albumin as the standard. Thirty micrograms of total protein from each sample was separated on duplicate SDS-PAGE gels (Thermo Fisher/Life Technologies, Carlsbad, CA, USA), and transferred onto polyvinylidene difluoride membrane (Bio-Rad Laboratories, Hercules, CA, USA), one for Western blot analysis, and the second was stained with Ponceau S solution (Sigma, St. Louis, MO, USA) to demonstrate the similar loading of retinal extract and transferring efficiency across all samples. The Western blot membrane was incubated overnight with a rabbit polyclonal RS1 antibody against the N terminus of retinoschisin (amino acid residues 24–37), and then was rinsed in 0.1% Tween-20 in sodium phosphate buffer (PBS) followed by incubation with IRDye 800CW conjugated goat anti-rabbit IgG (Cat # 926-32211; LI-COR Biosciences, Lincoln, NE, USA). Blot was scanned on LI-COR Odyssey Infrared Imaging System (Model 9120; LI-COR Biosciences, Lincoln, NE, USA).

**Immunofluorescent assays.** Animals were euthanized, and the eye globe was enucleated with the third eyelid retained. This was fixed in 4% paraformaldehyde (PFA) in sodium phosphate buffer (PBS) on ice for 30 min, and then cooled and later stored to remove the eye. The eyebags were returned to fixation buffer for 1.5 h and processed for cryosectioning. The 10 μm sagittal cryosections were cut for immunofluorescent assay [13]. Briefly, retinal sections were rinsed in washing buffer (0.1% Triton X-100 in PBS) and preincubated with PBS containing 20% normal goat serum (Sigma, Steinheim, Germany) and 0.3% Triton X-100 at room temperature (RT) for 2 h to block nonspecific antibody binding. The retinal sections were incubated overnight at 4 °C with a rabbit polyclonal antibody against the N-terminus of retinoschisin (amino acid residues 24–37; 1:1000, customized antibody, Thermo Fisher Scientific, Waltham, MA, USA) and/or a monoclonal antibody against the PKCα (1:500, Santa Cruz, Dallas, TX, USA) in PBS buffer containing 5% normal goat serum, after rinsing with washing buffer, sections were incubated with an secondary antibody conjugated to red-fluorescent Alexa Fluor 568 dye or green-fluorescent Alexa Fluor 488 dye (Thermo Fisher Scientific, Waltham, MA, USA) for 1 h at room temperature. The nuclei were stained with 40,60-diamidino-2-phenylindole (DAPI; Thermo Fisher Scientific, Waltham, MA, USA) in washing buffer, and sections were mounted with Fluoro gel (Electron Microscopy Sciences, Hatfield, PA, USA). Retinal images were obtained and processed with a Nikon C2 confocal microscope with Advanced Element software (Nikon, Tokyo, Japan). Image analysis was performed using image-editing software (Photoshop CS6; Adobe Systems, Inc., San Jose, CA, USA).

**Optical coherence tomography (OCT)**

*OCT image collection.* Retinal OCT optical images were obtained with the Envisu R2200 SD-OCT (Bioptigen, Durham, NC, USA). Animals were anesthetized by intraperitoneal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg). Pupils were dilated with tropicamide and phenylephrine. Artificial tears (Alcon Laboratories, Inc., Fort Worth, TX, USA) were used throughout the procedure to maintain corneal clarity. For rats at p8-p10 the angle to the eye was oriented for maximum viewing of the retina. Each an average of 1000 μm to 1170 μm away from optic nerve head (i.e., 51–250 pixels from image edge) were measured. Each image was binned every 10 pixels, and the lines of inner limiting membrane (ILM), external boarder of inner plexiform layer (IPL), and Bruch’s membrane (BM) from both WT and Rs1h−/− OCT images were marked and user verified. Thickness from ILM to IPL was measured for evaluating inner retinal thickness. Retinal distal portion from external board line of IPL to BM was measured because outer retina from ONL to RPE cannot be measured directly due to the indistinctive boarder lines for INL, OPL, and ONL in Rs1h−/− rat. As the INL cell counts in Rs1h−/− were the same as WT at all ages checked, we postulated that the INL thickness of both WT and Rs1h−/− in OCT images should also be similar. Therefore, INL thickness of WT retina was measured, and the values were used to calculate outer retina thickness (OPL to RPE) for both WT and Rs1h−/− mice.

**Histology.** Eyes were enucleated from euthanized animals and fixed in 10% formalin for histology examination. After dehydration, the eye globes were embedded in rapid polymerizing methyl methacrylate. Sagittal semithin sections were cut through the center of eye, and these including ON head were stained with hematoxylin and eosin (H&E). Retinal images were collected using an Axio Scan Z1. Zeiss microscope (Carl Zeiss Microscopy, Jena, Germany) and analyzed using image-editing software (Photoshop CS6; Adobe Systems, Inc., San Jose, CA, USA). The ONL and INL cells of inferior and superior retina were counted separately between 500 and 1000 μm from the optic nerve (ON) using an automated method with ImageJ software (http://image.nih.gov/j) provided in the public domain by the National Institutes of Health, Bethesda, MD, USA). The cell counts per 100 μm length of retina was used to evaluate the ONL and INL cell number. For the natural history study, eye globes from Rs1h−/− male rats and WT littermates were collected at p15, p21, p28, and 2, 3 and 6 mo. H&E stained sagittal semithin sections including the ON head were evaluated. For heterozygous females, retinal morphology was evaluated at 1, 3, 6, and 12 mo. Each group included at least 5 Rs1h−/− rats or 3 Rs1h+/− rats and 2 WT rats.

**Electroretinography (ERG).** Full-field ERGs were recorded from 13 male Rs1h−/− and 7 male WT Long Evans rats at p27-p28 using an Espion E2 system (Diagnosys, Lowell, MA). Animals were dark adapted overnight and then anesthetized with intraperitoneal ketamine (100 mg/kg) and xylazine (6 mg/kg). The pupils were dilated with topical 0.5% tropicamide and 2.5% phenylephrine HCl. Rats were placed on a heating pad to maintain body temperature. ERGs were recorded with gold loop wires placed on the cornea with a drop of methylcellulose after application of 1% proparacaine topical anesthetic. A gold wire was placed in the mouth as the differential electrode, and a ground wire was attached to the tail. Dark-adapted ERG responses were elicited with flash intensities from −3.8 to 0.7 log cd.s/m2 in 0.5-log steps. Ganzfeld (full-field) stimuli were delivered by a ColorDome sphere (Diagnosys, Lowell, MA), with interstimulus intervals of 3–60 s depending on stimulus intensity. Responses were frequency filtered using a 0.3–300 Hz bandpass and a 60–Hz line-frequency filter. A-waves were measured from the pre-stimulus baseline to the initial negative trough. B-waves were measured from the baseline or from the a-wave trough when present. Intensity-response relations of the a- and b-waves elicited by low intensity flash (−3.8 to −0.7 log cd.s/m2) are primarily from the rod photoreceptor circuits. They were fitted (GraphPad Prism V9; GraphPad Software Inc.) by the Naka-Rushton equation:

\[ R = \frac{R_{\text{max}}}{1 + (I/I_0)^n} + R_{0} \]

where \( R_{\text{max}} \) is the maximal response amplitude, \( I \) is the flash intensity, \( n \) is the Hill coefficient, and \( K \) is the half-saturation constant.

**Mutant Rs1h mRNA detection and confirmation.** Reverse transcript (RT)-PCR was performed to detect the message RNA (mRNA) of Rs1h. Retinas were collected, and the total RNA was extracted and purified using RNAzol RT (Sigma, St. Louis, MO, USA). The 2 μg of total RNA was used to...
synthesize first strand cDNA with random primers and M-MLV reverse transcriptase (Invitrogen, Eugene, OR, USA). Rs1h transcript was amplified using cDNA templates, a pair of Rs1h gene specific primers and platinum Taq polymerase (Invitrogen, Eugene, OR, USA). The sequence of the forward primer was 5'-AGGCTTCTTCTTATTGCTTCTCTT-3', the sequence of the reverse primer was 5'-AGTCGGATGAAGCGGGAAATAATG-3'. PCR tests were performed with 22 cycles, a number empirically determined within the linear range of PCR analysis (data not shown). RT-PCR products were visualized in Flashing gel system (Lonza, Alpharetta, GA, USA), and images were taken using FlashGel camera (Lonza, GA, USA). The Density of RT-PCR bands was analyzed using Image J 1.48 v (http://imagej.nih.gov/ij; provided in the public domain by the National Institutes of Health, Bethesda, MD, USA). RT-PCR products were purified with QIAquick PCR Purification Kit (Qiagen, Germantown, MD, USA) and the RT-PCR products were sequenced and compared with the expected target DNA sequence.

**AAV delivery of human RS1 gene augmentation.** Rs1h−/− male rats were administrated 2e10 viral genome per eye of scAAV8-hRS/IRBP-hRS, the vector used in our XLRS clinical trial [9], at p7-p8 following the procedure as described previously [7, 12]. One eye was administrated vector by intravitreal injection, and contralateral eye was an untreated control. Twelve weeks post injection (PI), OCT images were collected, and eyes were enucleated and prepared for cryo-sectioning. The vector expression of RS1 and retinal morphology was assessed as described previously [7]. Immunofluorescent images were captured using the Nikon C2 confocal microscope as described above.

**RESULTS**

**Generation of Rs1h−/− Exon-3 deletion XLRS rat model**

Figure 1A depicts the strategy of generating Rs1h−/− rat with CRISPR/Cas9 system using guide RNA1 (gRNA1) located within intron 2 and guide RNA2 (gRNA2) within intron 3. These two gRNAs lead Cas 9 endonuclease to the target region and make DNA breaks followed by non-homologs end-joining which excises exon 3. Two founders were generated with exon-3 deletions (Fig. 1C), and colonies were established. As they had essentially the same phenotype, results were pooled. Genotypes were determined using forward primers upstream of gRNA1 and a reverse primer downstream of gRNA2, and the targeted region encompassing
exon 3 was amplified. This gives a 1051 base pair (bp) fragment for the WT allele (Fig. 1B, large band, yellow arrow) and a smaller 750 bp fragment for the Rs1h knockout allele (Fig. 1B, red arrow). DNA sequencing confirmed that the deletion encompassed exon 3 plus partial sequence of adjoining intron 2 and intron 3 (Fig. 3C, yellow highlight). The loss of exon 3 causes an Rs1h frameshift downstream which results in multiple premature termination codons (PTCs).

Characterization of Rs1h<sup>−/−</sup> rat

Loss of normal Rs1h protein in Rs1h<sup>−/−</sup>. The absence of normal Rs1h protein was confirmed by Western blot and immunohistochemistry (IHC). Total retinal protein extracts (Fig. 2B left) were analyzed using a polyclonal Rs1 antibody against amino acid 24-37 that are translated from exons 2 and 3 (Fig. 2A). This showed a 24 kDa band corresponding to the WT normal size Rs1h protein (Fig. 2B, right panel, lane 1 and 4) and also for the Rs1h<sup>−/−</sup> heterozygote (Fig. 2B, right panel, lane 3 and 6), but this was absent for Rs1h<sup>−/−</sup> males (Fig. 2B, right pane, lane 2 and 5, red arrows). IHC analysis of retinal sections with this antibody detected no Rs1h protein expression in Rs1h<sup>−/−</sup> retina (Fig. 2C right), whereas WT retina showed retinoschisin expression in multiple retinal layers, including the inner segment layer (IS), outer plexiform layer (OPL) and inner nuclear layer (INL) (Fig. 2C, left) as expected for WT mouse [20, 21].

Morphological abnormalities and natural history study. The Rs1h<sup>−/−</sup> retina was evaluated for morphologic change using OCT imaging (Fig. 3A, a) and H&E stained histology sections (Fig. 3A, b) at six ages (p15 to 6 mo). OCT images of WT retina (Fig. 3A, a, top panel) shows normal organized lamellar structure with defined OCT reflective bands out to 6 mo age, including GCL, IPL, INL, OPL, ONL, and the normal four outer retinal reflective bands (ORRB, i.e., OLM, IS/ep, interdigitation zone and RPE). By comparison, the laminar structure of Rs1h<sup>−/−</sup> was disrupted (Fig. 3A, a, second panel) and had large schisis
Phenotype features of Rs1h<sup>−/−</sup> rat model. OCT retinal images (Fig. 3Aa) and semithin histology sections (Fig. 3Ab) show retinal morphology changes at six ages (p15, p21, p28, 2 mo, 3 mo and 6 mo). Fig. 3Aa bottom, retinal morphology of Rs1h<sup>−/−</sup> rat shows a giant cavity by age p15, which narrowed to a crevice in INL by p21 (red arrows), and nearly disappeared by p28 (green arrows) (normal retinal morphology of WT, Fig. 3Aa top). The ONL thinned rapidly with age, retinal laminar structure was disrupted, and the OPL to OS margin became indistinctive. The INL had irregular boarders, but INL thickness remained relatively normal. Rs1h<sup>−/−</sup> retinal histology at corresponding ages (Fig. 3Ab, bottom) showed abnormalities similar that on OCT. The giant splitting cavity was found in INL at p15. The ONL layer was similar to WT at p15 but rapidly thinned from cell loss from age p21, and only 1 to 3 layers remained by age 6 mo. ONL structure was disrupted by p15, and photoreceptor nuclei were misplaced into the IS and OS regions and the OPL (Fig. 3Ab, bottom, yellow arrows). Both OPL and IS/OS zone narrowed with age and were essentially absent by age 6 mo. GCL ganglion cell layer, IPL inner plexiform layer, INL inner nuclear layer, OPL outer plexiform layer, ONL outer nuclear layer, ILM inner limiting membrane, IS inner segment, OS outer segment, ORRBs outer retinal reflective bands. Scale bars: 200 μm horizontal; 100 μm vertical in OCT images. 50 μm for semi-thin histology sections. Fig. 3Ba shows retinal layer thickness in 8–15 Rs1h<sup>−/−</sup> eyes and 4–8 WT eyes at each age. The outer retina from OPL to RPE shows progressive thinning (left), with reductions of 30% at p21, 34% at p28, 44% at 2 mo, 56% at 3 mo, and 71% at 6 mo (all significant versus WT, unpaired t test, p < 0.0001). Thickness of the inner retina from ILM to IPL remained normal at each age (right plot). Fig. 3Bb shows ONL and INL cell counts from at least 3 Rs1h<sup>−/−</sup> and age-matched WT controls at each age. ONL cell numbers for Rs1h<sup>−/−</sup> were 250 ± 25 (mean ± SEM), or 29 % reduced at p21; 163 ± 22, or 50% reduced at p28; 92 ± 22, or 64% reduced at 3 mo; 32 ± 25, or 85% reduced at 6 mo (all significant versus WT by Sidak’s multiple comparisons test, p ≤ 0.004). The INL had not significantly loss of cells versus WT (Fig. 3Bb, right plot) *(color figure online)*.
cavities spanning the INL by p15, and by p21 the cavities were already collapsed to only narrow crevices in the INL (3Aa, bottom panel, red arrows). By p28 they continued to reduce further (Fig. 3Aa, bottom panel, green arrows) and disappeared by 2 mo age. The OPL boundary was irregular and the ONL thinner by p21, and the ORBB morphology was distorted and indistinct. ONL thickness continued to diminish rapidly with age. These changes were seen across the retina from center to periphery.

Rs1h<sup>−/−</sup> retinal histology showed abnormalities corresponding to those observed on OCT across these age (Fig. 3Aa, b, bottom). Histology showed giant schisis cavities in INL at p15 (Fig. 3Aa, b, bottom, left), and the rows of ONL nuclei initially were similar to WT but then thinned rapidly from cell loss beginning by p21. Only 1 to 3 layers of ONL remained by 6 mo age. At p15 the ONL lamination was considerably disrupted, with many photoreceptors misplaced into the IS/OS region and into the OPL (Fig. 3Aa, b, bottom, yellow arrows). The width of the OPL and IS/OS zones both diminished with age and were essentially absent by 6 mo age. The INL had irregular boarders but retained a normal cell count.

Thickness of the retinal layers was measured on OCT images, and ONL and INL cell numbers were counted on histologic sections from p21 to 6 mo. The effect of age on layer thinning and outer retina cell loss was evaluated (Fig. 3B). Thickness of the outer retina from OPL to RPE was reduced 30% at p21, 34% at p28, 44% at 2 mo, 56% at 3 mo, and 71% at 6 mo, and all changes were significant compared with WT (unpaired t test, p < 0.0001) (Fig. 3B, a, left plot). The ONL cell count was 29% diminished at p21, 50% at p28, 64% at 3 mo, and 85% at 6 mo, and again all changes were significant between Rs1h<sup>−/−</sup> and WT (Sidak’s multiple comparisons test, p ≤ 0.004) (Fig. 3B, b, left plot). No significant difference was noted in inner retinal thickness (Fig. 3B, a, right plot) or for INL cell number of Rs1h<sup>−/−</sup> versus WT rats (Fig. 3B, b, right plot).

**Retinal functional status**

Retinal function was evaluated by ERG recordings at p27-28. Figure 4A shows a series of dark-adapted ERGs of Rs1h<sup>−/−</sup> and WT rats, and averaged intensity-response relations for the a- and b-waves are shown in Fig. 4B. The continuous curves are a fitting of the data by the Naka-Rushton equation. Rs1h<sup>−/−</sup> rats showed diminished a-wave amplitudes with R<sub>max</sub> of 196 µV versus 421 µV for WT, consistent with the ONL cell loss (Fig. 3Ab). The function of b-wave amplitude to stimulus flash luminance has two limbs, with low flash responses up to −0.7 log cd · s/m<sup>2</sup> dominated by rod inputs, and a separate limb for high flash intensities which elicits activity of both rods and cones (termed: mixed inputs) [22–24]. Fitting of the Naka-Rushton equation to the low intensity limb yielded R<sub>max</sub> of 919 µV for WT and 341 µV for Rs1h<sup>−/−</sup>, a 63% reduction.

An indication of the input/output relationship for the rod synapse was analyzed using the ratio of R<sub>max</sub> for the rod-driven b-wave versus the a-wave, and the (b-/a-wave) ratio was seen to be reduced from 2.18 in WT to 1.73 for Rs1<sup>−/−</sup>. We also determined the synaptic signaling integrity using b-wave amplitude elicited at −1.8 log cd · s/m<sup>2</sup> which is purely rod-driven; the a-wave amplitude was elicited at 0.70 log cd · s/m<sup>2</sup> is also purely rod-driven [22]. This gave a similar result for the averaged (b-/a-wave) ratio of 2.25 ± 0.09 for WT (mean ± SEM, n = 7) and 1.71 ± 0.13 for Rs1h<sup>−/−</sup> (mean ± SEM, n = 14), which was significant (p < 0.05; two-way ANOVA). Under the assumption that the mechanism responsible for generating the b-wave was intact, this change reflects deficient synaptic transmission from rod photoreceptors to the rod bipolar cells [7, 25].

Rs1h<sup>−/−</sup> also showed reduced sensitivity for both the a- and b-waves, indicated by the Naka-Rushton K value. The K value for the Rs1h<sup>−/−</sup> a-wave was 0.70 log cd · s/m<sup>2</sup> which is considerably higher than the WT a-wave K value of −0.12 log cd · s/m<sup>2</sup> (0.82 log unit difference). The K value of the Rs1<sup>−/−</sup> b-wave was also considerably higher (−1.76 log cd · s/m<sup>2</sup>) than for WT (−2.63 log cd · s/m<sup>2</sup>), or a 0.87 log unit sensitivity reduction for the XLR5 model. This is consistent with reduction of quantum catch in Rs1h<sup>−/−</sup> photoreceptors most likely due to shortened and disorganized ROS [26].

**No deleterious gain-of-function in Rs1h<sup>−/−</sup> heterozygous females with mutant Rs1h mRNA**

The mutant Rs1h mRNA in this model causes a framework with PTCs which normally undergoes nonsense-mediated mRNA decay (NMD) to prevent production of harmful truncated protein [27–33]. RT-PCR analysis was performed to determine relative level of mutant Rs1h transcription in transgenic rats (Fig. 5). The RT-PCR band density was considerably reduced in Rs1h<sup>−/−</sup> retina versus WT, and the density of mutant Rs1h band was also significantly lower than normal Rs1h in the Rs1h<sup>−/−</sup> heterozygous female retina, indicating the majority of mutant Rs1h mRNA was eliminated by NMD, as expected. The DNA sequencing analysis indicated that no exon 3 sequences (106 bp) were identified (Fig. 5B, yellow highlighted), and that exon 2 (Fig. 5B, green highlighted) connected directly to exon 4 (Fig. 5B, pink highlighted) without exon 3 in the Rs1h mutant retinas (Fig. 5B, yellow highlighted). The DNA sequence analysis confirmed that a small quantity of Rs1h mutant mRNA was present in the knockout samples (Fig. 5A, red arrows).

We evaluated for potential toxic effects of truncated protein by close analysis of retinal morphology of Rs1h<sup>−/−</sup> heterozygous female retinas at five ages, from 1 to 12 mo (representative histologic morphology is shown with age matched WT, in Fig. 5C). No differences could be detected in comparing mutant to WT.
from augmentation with normal RS1, which had been demonstrated previously for the Rs1h−/− mouse which gained better retinal morphology and function after gene transfer [1, 7, 10–12]. Rs1 was delivered to Rs1h−/− eyes at p7-p8 when ONL cell development appeared similar to WT and showed no evident ONL loss (Fig. 6). Twelve weeks after treatment the appearance of the retinal laminar structure was more organized and the OPL and ONL margins were more distinct. On OCT imaging the line representing the OLM reflective band was better defined (6A, green arrows), and the subretinal space was partially preserved (6A, red arrowhead). Similar OCT improvements had previously been found for Rs1h−/− mouse retina after AAV8-RS1 treatment [12].

Retinal immunofluorescent images of Rs1h−/− eyes after AAV8-RS1 treatment are shown in Fig. 6B, one resulting in high RS1 expression (Fig. 6, b and f) and a second with less RS1 expression (Fig. 6, c and g), along with an untreated Rs1h−/− retina (Fig. 6, d & h). The Rs1h−/− retina with high RS1 expression showed an expression pattern equivalent to WT, with well organized retinal laminar structure and preservation of all layers as in WT, although the ONL was thinner (Fig. 6a and b). Furthermore, the on-bipolar cells (PKCa labeled) exhibited better organization of photoreceptor synapse to on-bipolar cells (which colocalize with RS1 protein) (Fig. 6e and f, white rectangular).

The Rs1−/− non-treated eye and the Rs1−/− retina with only little RS1 expression both display an interrupted pattern of outer retinal structure, with some photoreceptors misplaced into the subretinal space (Fig. 6a, c, d, g and h; yellow circles). Ectopic neurites processes of bipolar cells extend into the ONL layer and the subretinal space (Fig. 6a and h, red arrows). For both the untreated retina and the retina with only low Rs1h expression, the ONL thickness is less than the retina with higher RS1 expression. This indicates that supplementing the Rs1h−/− retina with normal RS1 improves the retinal dysmorphology considerably. This pattern of recovery after providing RS1 at early developmental age is evidence that the degenerative phenotype in Rs1h−/− eyes was the result of Rs1h deficiency and not off-target or toxic-gain function activity.

**DISCUSSION**

A rat model of XLRS has advantages over mouse models in eye and body size. Rat genetic retinal dystrophy models were once used widely in medical research until mouse embryonic stem cells (ESCs) became available [34]. The larger body size of rat versus mouse and supports serial blood samples from single animals over time, and this facilitates monitoring humoral immune responses to therapeutic compounds. The rat eye has threefold greater retinal surface area than mouse, and a vitreous cavity is ten-times larger (rat 54.4 μl versus mouse 5.4 μl) [35, 36]. These anatomic advantages make surgical procedures with the rat eye safer and easier, and the larger eye facilitates ocular drug delivery which should increase consistency of result and interpretation than the tiny mouse eye.

The Rs1h exon-3-del knockout rat XLRS model showed severe disease phenotype by early age and progressed rapidly compared to the exon 1 deletion Rs1h−/− mouse we made previously [1]. This XLRS rat showed generalized disruption of retinal structure, loss of laminar integrity of the OPL and INL, and photoreceptors misplaced into both the OPL and the subretinal space as early as p15. The outer retina of Rs1h−/− rat was significantly thinner than WT even by age p21, and rapid loss of photoreceptor cells ensued with only 1–3 rows of nuclei remaining by 6 mo age (70–90% ONL cell loss). Rs1h-mutant XLRS mouse models are heterogeneous, and this rate of degeneration was observed in the Rs1h−/− mice generated by the Weber group in which about half of photoreceptor cells were lost and rod outer segment (ROS) was nearly completely lost by 2 mo age [2]. The Rs1h−/− rat had remarkably large cavities at p15, similar to the Rs1h−/− mice created by Liu et al, which included replacing exon 1-3 with LacZ
reporter gene one Rs1h−/+ mouse model, and two knock-in mouse models carrying either a CS9S or an R141C point mutant substitution [3]. Except for the exon 1 deletion Rs1h−/+ mouse we made previously, the phenotype onset and progression of this rat model roughly follows that of the faster of the current mouse models (Table 1) [2, 3, 37, 38]. What appears different in this rat model is the rapid emergence and collapse of the schisis cavities. These form over only a few days from P8 to p15, and they then diminish dramatically in only 1–2 weeks, which is different from the mouse models. The basis for the range of phenotype remains unclear, but heterogeneity is also found for human XLRS individuals.

The Rs1h−/+ exon-3-del rat phenotype appears more severe at early age than most XLRS patients, less frequently show much reduction of the photoreceptor ERG a-wave across the lifespan [44]. Before concluding that the phenotype is due to Rs1h deficiency, we screened for off-target CRISPR-Cas9 effects, but none were identified. Off-target effects are diluted by mating with WT as the phenotype severity will become milder successive generations [45, 46]. However, the severity of Rs1h−/+ pathology remained consistent across generations 1–4, nor did the heterozygous females exhibit retinal dysmorphism which off-target effects would cause. In addition, the size, weight, appearance, reproductivity and lifespan of the Rs1h−/+ rats are comparable to WT. While nonsense mediated decay would quickly degrade most mRNA that contains PTCs [27, 30, 31, 33], a small proportion of aberrant Rs1h mRNA was detected in both Rs1h−/+ homozygous Rs1h−/+ retinas. However, abnormal morphology was not found in heterozygous Rs1h−/+ females, and we conclude that mutant Rs1h mRNA does not itself cause disease in this rat model. This is consistent with the Rs1h−/+ mouse created by Liu et al. [3], and it is also constant with lack of clinical findings for human female Rs1h−/+ carriers who with rare exception do not show retinal pathology despite carrying an Rs1 nonsense mutant allele [47–49]. Additional

**Fig. 6** Rs1 gene augmentation gives morphologic improvement of Rs1h−/+ retina on OCT (Fig. 6A, middle) compared with WT (left) and untreated Rs1h−/+ retina (right). Treated retina had more organized lamina, with more distinct OPL and ONL margins (yellow arrows). OLM was better defined (green arrows), and subretinal space was preserved (red arrowhead). B Shows immunofluorescent retinal images with Rs1 antibody (top panel) and Rs1/PKCα (red/green) (bottom panel). The images of treated retina were selected from two different regions of one treated rat eye, one with greater Rs1 expression (B and F), and the second with minimal expression (C and G). The treated Rs1h−/+ retina with high RS1 expression has WT RS1 distribution pattern, and organized retinal laminar structure is well organized with all layers preserved. ON-bipolar cells (PKCα label) show an organized synaptic distribution between neurons, as in WT retina (E and F, white rectangular). By comparison, both the untreated Rs1h−/+ retina (D & H) and the low expressing Rs1h−/+ retina (C & G) display an interrupted outer retinal structure, with photoreceptors intruding into the subretinal space (C, D, G and H, yellow circles) and bipolar cell fibers extending into the ONL and subretinal space (C, D, G and H, red arrows). GCL ganglion cell layer, IPL inner plexiform layer, INL inner nuclear layer, OPL outer plexiform layer, ONL outer nuclear layer, IS inner segment, OS outer segment. Scale bars: OCT, 200 μm horizontal and 100 μm vertical; 50 μm for histology sections (color figure online).
Table 1. Phenotype comparison of XLRS rat to XLRS mouse models.

| Phenotype | Schisis cavities | Photoreceptor | ERG | Reference |
|-----------|-----------------|---------------|-----|-----------|
| Rs1hfi | first seen lamellar structure | maximum resolved ONL loss | ONL loss | Current paper |
| Rat | p8 to p15 | p15 | 5-6 M | Ref. # [3, 37] |
| | | | | |
| Mouse E3 deletion | p18 | No data | 2 M | No data |
| | | | | Ref. # [38] |
| Mouse E1-3 | p15 | after 4 M | 2-3 M | No data |
| | | | | Ref. # [3] |
| Mouse C59S substitution | p15 | after 4 M | 2-3 M | No data |
| | | | | Ref. # [3] |

ONL, Outer Nuclear Layer; ROS, rod outer segments.

Supporting evidence comes from supplementing the Rs1hfi retina with a normal RS1 gene via AAV8-RS1 delivery, as this helped preserve retinal laminar structure in the Rs1hfi male retina and partial preserved reduced the photoreceptor loss. On these bases, we propose that the XLRS rat phenotype results from lack of normal RS1 protein and is a suitable model of an Rs1h-deficient animal.

This Rs1hfi rat XLRS model shares disease features with human XLRS, including the development of schisis cavities within OPL and INL, degeneration of photoreceptors with age although, and a relative reduction in ERG b-wave to a-wave amplitudes. While this rat model does not show a "negative ERG waveform," this occurs in about half of human XLRS cases, and the reduced (b-/a-wave) ratio in this rat, as in many XLRS humans, is consistent with impaired synaptic transmission from rod photoreceptors to their bipolar cells [7, 38]. Administering the AAV8-RS1 vector at age p7-p8 shows the presence of a therapeutic window in this rat model to monitor treatment outcome, but it will be most useful at young age before structural loss of photoreceptors. We do not yet know whether the positive outcome with AAV8-RS1 results from preservation of cells or a reduction in loss, or both.

REFERENCES

1. Zeng Y, Takada Y, Kjellstrom S, Hirayanna K, Tanikawa A, Wawrousek E, et al. RS-1 gene delivery to an adult Rs1h knockout mouse model restores ERG b-wave with reversal of the electronegative waveform of X-linked retinoschisis. Invest Ophthalmol Vis Sci. 2004;45:3279-85.
2. Weber BH, Schrewel MA, Molday LL, Gehrig A, White KL, Seeliger MW, et al. Inactivation of the murine X-linked juvenile retinoschisis gene, Rs1h, suggests a role of retinoschisin in retinal cell layer organization and synaptic structure. Proc Natl Acad Sci USA. 2002;99:6222-7.
3. Liu Y, Kinoshita J, Ivanova E, Sun D, Li H, Liao T, et al. Mouse models of X-linked juvenile retinoschisis have an early onset phenotype, the severity of which varies with genotype. Hum Mol Genet. 2019;28:3072-90.
4. Chen D, Xu T, Tu M, Xu J, Zhou C, Cheng L, et al. Recapitulating X-linked juvenile retinoschisis in mouse model by knock-in patient-specific novel mutation. Front Mol Neurosci. 2017;10:453.
5. Tantti A, Vrabec TR, Cu-Unjiong A, Frost A, Annesley WH Jr., Donoso LA. X-linked retinoschisis: a clinical and molecular genetic review. Surv Ophthalmol. 2004;49:214–30.
6. Sikkink SK, Bivas S, Parry NR, Stanga PE, Trump D. X-linked retinoschisis: an update. J Med Genet. 2007;44:225–32.
7. Bush RA, Zeng Y, Colosi P, Kjellstrom S, Hirayanna S, Vijayasarthi C, et al. Pre-clinical dose-escalation study of intravitreal AAV-RS1 gene therapy in a mouse model of X-linked retinoschisis: dose-dependent expression and improved retinal structure and function. Hum Gene Ther. 2016;27:376-89.
8. Byrne LC, Ozturk BE, Lee T, Fortuny C, Visel M, Dalkara D, et al. Retinoschisin gene therapy in photoreceptors, Muller glia or all retinal cells in the Rs1h-/- mouse. Gene Ther. 2014;21:585–92.
9. Cuckras C, Wyley HE, Jeffrey BG, Sen HH, Turnbull A, Zeng Y, et al. Retinal AAV8-RS1 gene therapy for X-linked retinoschisis: initial findings from a phase I/IIa trial by intravitreal delivery. Mol Ther. 2018;26:2282–94.
10. Dalkara D, Byrne LC, Klimczak RR, Visel M, Yin L, Merigan WH, et al. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med. 2013;5:189ra176.
11. Min SH, Molday LL, Seeliger MW, Dinculescu A, Timmers AM, Janssen A, et al. Pro-Longed recovery of retinal structure/function after gene therapy in an Rs1h-deficient mouse model of X-linked juvenile retinoschisis. Mol Ther. 2005;12:644–51.
12. Zeng Y, Petralia RS, Vijayasarthi C, Wu Z, Hirayanna S, Song H, et al. Retinal structure and gene therapy outcome in retinoschisin-deficient mice assessed by spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2016;57:OCT277–287.
13. Zeng Y, Qian H, Wu Z, Marangoni D, Sieving PA, Bush RA. AAV-Rh10 transduces outer retinal cells in rodents and rabbits following intravitreal administration. Gene Ther. 2019;26:386–98.
14. Marangoni D, Bush RA, Zeng Y, Wei LL, Zizzardi L, Vijayasarthi C, et al. Ocular and systemic safety of a recombinant AAV8 vector for X-linked retinoschisis gene therapy: GLP studies in rabbits and Rs1-KO mice. Mol Ther Methods Clin Dev. 2016;5:18011.
15. Birling MC, Herault Y, Pavlovic G. Modeling human disease in rodents by CRISPR/Cas9 genome editing. Mamm Genome. 2017;28:291–301.
16. Gupta D, Bhattacharjee O, Mandal D, Sen MK, Dey D, Dasgupta A, et al. CRISPR-Cas9 system: a new-fangled dawn in gene editing. Life Sci. 2019;232:116636.
17. Komor AC, Badran AH, Liu DR. CRISPR-based technologies for the manipulation of eukaryotic genomes. Cell. 2017;169:539.
18. He Z, Proudfoot C, Mileham AJ, McLaren DG, Whitelaw CB, Lillico SG. Highly efficient targeted chromosome deletions using CRISPR/Cas9. Biotechnol Bioeng. 2015;112:1060–4.
19. Ahmed B, Arif M, Qadir MI. CRISPR/Cas9: a successful tool for genome editing in animal models. Crit Rev Eukaryot Gene Expr. 2020;30:239–43.
20. Takada Y, Faniss RN, Tanikava A, Zeng Y, Carper D, Bush R, et al. Retinal neuronal developmental wave of retinoschisin expression begins in ganglion cells during layer formation. Invest Ophthalmol Vis Sci. 2004;45:3302–12.
21. Molday LL, Hicks D, Sauer CG, Weber BH, Molday RS. Expression of X-linked retinoschisin protein RS1 in photoreceptor and bipolar cells. Invest Ophthalmol Vis Sci. 2001;42:816–25.
22. Weymouth AE, Yingrys AJ. Rodent electroretinography: methods for extraction and interpretation of rod and cone responses. Prog Retin Eye Res. 2008;27:1–44.
23. Peachey NS, Alexander KR, Fishman GA. The luminance-response function of the dark-adapted human electroretinogram. Vision Res. 1989;29:263–70.
24. Toda K, Bush RA, Humphries P, Sieving PA. The electroretinogram of the rhodopsin knockout mouse. Vis Neurosci. 1999;16:391–8.
25. Machida S, Raz-Prag D, Faniss RN, Sieving PA, Bush RA. Photopic ERG negative response from amacrine cell signaling in RCS rat retinal degeneration. Invest Ophthalmol Vis Sci. 2008;49:442–52.
26. Massof RW, Wu L, Finkelstein D, Perry C, Starr SJ, Johnson MA. Properties of electroretinographic intensity-response functions in retinitis pigmentosa. Doc Ophthalmol. 1984;57:279–96.
27. Baker SL, Hogg JR. A system for coordinated analysis of translational readthrough and nonsense-mediated mRNA decay. PLOS One. 2017;12:e0173980.
28. Carrier L, Schlossarek S, Willis MS, Eschenhagen T. The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy. Cardiovasc Res. 2010;85:330–8.
29. Karamyshev AL, Karamysheva ZN. Lost in translation: ribosome-associated mRNA and protein quality controls. Front Genet. 2018;9:431.
30. Kurosaki T, Maquat LE. Nonsense-mediated mRNA decay in humans at a glance. J Cell Sci. 2016;129:461.
31. Moon H, Zheng X, Loh TJ, JangHN, Liu Y, Jung DW, et al. Effects of PTCs on nonsense-mediated mRNA decay are dependent on PTC location. Oncol Lett. 2017;13:1944–8.
32. Nasif S, Contu L, Muhlemann O. Beyond quality control: the role of nonsense-mediated mRNA decay (NMD) in regulating gene expression. Semin Cell Dev Biol. 2018;88:207–15.
33. Shi M, Zhang H, Wang L, Zhu C, Sheng K, Du Y, et al. Premature termination codons are recognized in the nucleus in a reading-frame dependent manner. Cell Discov. 2015;1:15001–21.
34. Iannaccone PM, Jacob HJ. Rats! Dis Model Mech. 2009;2:206.
35. Hughes A. A schematic eye for the rat. Vision Res. 1979;19:569–88.
36. Remtulla S, Hallett PE. A schematic eye for the mouse, and comparisons with the rat. Vision Res. 1985;25:21–31.
37. Janssen A, Min SH, Molday LL, Tanimoto N, Seeliger MW, Haushworth WJ, et al. Effect of late-stage therapy on disease progression in AAV-mediated rescue of photoreceptor cells in the retinoschisin-deficient mouse. Mol Ther. 2008;16:1010–7.
38. Kjellstrom S, Bush RA, Zeng Y, Takada Y, Sieving PA. Retinoschisin gene therapy and natural history in the Rh1 KO mouse: long-term rescue from retinal degeneration. Invest Ophthalmol Vis Sci. 2007;48:3837–45.
39. Ome’lchenko AV, Korchagin VI, Sevastianova GA, Ryskov AP, Tokarskaia ON. [Molecular genetic characterization of dinucleotide loci in parthenogenetic lizards Darevskia unisexualis]. Genetika. 2009;45:230–8.
40. Neriyanur S, Dhandayuthapani S, Arunachalam JP, Raman R. Phenotypic characterization of X-linked retinoschisis: Clinical, electroretinography, and optical coherence tomography variables. Indian J Ophthalmol. 2016;64:513–7.
41. Iannaccone A, Mura M, Dyka FM, Ciccarielli ML, Yashar BM, Ayagari R, et al. An unusual X-linked retinoschisis phenotype and biochemical characterization of the W112C RS1 mutation. Vision Res. 2006;46:3845–52.
42. Machida S, Kondo M, Jamison JA, Khan NW, Kononen LT, Sugawara T, et al. P23H rhodopsin transgenic rat: correlation of retinal function with histopathology. Invest Ophthalmol Vis Sci. 2000;41:3200–9.
43. Ou J, Vijayasarathy C, Ziccardi L, Chen S, Zeng Y, Maragoni D, et al. Synaptic pathology and therapeutic repair in adult retinoschisis mouse by AAV-RS1 transfer. J Clin Invest. 2015;125:2891–903.
44. Bowles K, Cukras C, Turriff A, Sergeev Y, Vitale S, Bush RA, et al. X-linked retinoschisis: RS1 mutation severity and age affect the ERG phenotype in a cohort of 68 affected male subjects. Invest Ophthalmol Vis Sci. 2011;52:9250–6.
45. Bassett A, Liu JL. CRISPR/Cas9 mediated genome engineering in Drosophila. Methods. 2016;69:128–36.
46. Liu Z, Cheng TT, Shi Z, Liu Z, Lei Y, Wang C, et al. Efficient genome editing of genes involved in neural crest development using the CRISPR/Cas9 system in Xenopus embryos. Cell Biosci. 2016;6:22.
47. Sieving PA, MacDonald IM, Chan S. X-linked juvenile retinoschisis. In: Adam MP, Ardinger HH, Pagon RA, et al. (eds). GeneReviews® (RR). Seattle (WA); 1993.
48. Lesch B, Szabo V, Kanya M, Varsanyi B, Somfai GM, Hargitai J, et al. Truncation of retinoschisin protein associated with a novel splice site mutation in the RS1 gene. Mol Vis. 2008;14:1549–58.
49. Huang Y, Mei L, Gui B, Su W, Liang D, Wu L, et al. A novel deletion mutation in RS1 gene caused X-linked juvenile retinoschisis in a Chinese family. Eye. 2014;28:1364–9.

ACKNOWLEDGEMENTS
We wish to thank iris Wise, Maria Santos and Jinho Li for technical assistance of animal breeding and husbandry, and histology preparation.

AUTHOR CONTRIBUTIONS
YZ designed and conducted the experiments, data collection and analysis and wrote the paper; HQ conducted the experiment and wrote paper; MC conducted the experiment; YL conducted the experiment; CV conducted the experiment; PAS designed the experiments and wrote the paper.

FUNDING
The study was supported by the Intramural Research Program of the National Institutes of Health, the National Eye Institute (DC000065); and by the UC Davis Medical School Dean’s Fund for laboratory startup to PAS.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Correspondence and requests for materials should be addressed to Paul A. Sieving.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.